Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oxford BioMedica plc (OXBDF)
OTHER OTC:OXBDF
Holding OXBDF?
Track your performance easily
Earnings Data
Report Date
―TBA Not Confirmed
Period Ending
―Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 14, 2019
|% Change Since: 3.69%
|Next Earnings Date:Sep 13, 2018
Earnings Call Sentiment|Neutral
The earnings call reflected a transformative year for Oxford Biomedica with significant strategic advancements and expansion into new markets. However, financial challenges such as operating losses and impairments indicate areas of concern. The outlook for 2024 remains positive with expected revenue growth driven by a strong pipeline and market demand.Company Guidance
During Oxford Biomedica's Q4 2023 earnings call, the company provided guidance for a promising financial outlook in 2024, expecting a revenue growth of 40% to 50% over the previous year, and aiming to achieve a broadly breakeven EBITDA. The company's strategic transformation into a global pure-play CDMO is underscored by a 51% increase in business development pipeline and a 54% growth in client order value. The business development pipeline now stands at USD 573 million, with the number of clients and programs increasing to 35 and 51, respectively. Oxford Biomedica also highlighted an 11% growth in revenue backlog, reaching GBP 104 million by the end of March 2024. Despite a challenging biotech funding environment, the company has managed to significantly expand its operations across the U.K., U.S., and EU, with a notable strategic acquisition of ABL Europe, adding approximately 150 CDMO experts and increasing its capacity in process and analytic development.Significant Growth in Business Development Pipeline
Oxford Biomedica achieved a 51% increase in business development pipeline and a 54% growth in client order value in 2023.
Expansion of Global Footprint
The company expanded its operations to the U.S. and the European Union by acquiring ABL Europe, adding approximately 150 CDMO experts to the group.
Launch of TetraVecta System
Introduced in May 2023, the TetraVecta system is a fourth-generation lentiviral vector delivery system, enhancing quality and potency of viral vectors.
Strong Revenue Growth Forecast for 2024
Oxford Biomedica anticipates a 40% to 50% revenue growth in 2024, driven by strategic initiatives and market expansion.
Diversification into AAV Projects
The company increased its AAV project portfolio from 0% to 41% in 2023, demonstrating a successful expansion beyond lentivirus.
---
OXBDF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OXBDF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Sep 23, 2024 | $4.88 | $4.80 | -1.64% |
| Apr 29, 2024 | $2.91 | $3.26 | +12.03% |
| Sep 20, 2023 | $3.12 | $3.49 | +11.86% |
| Apr 25, 2023 | $5.69 | $5.66 | -0.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Oxford BioMedica plc (OXBDF) report earnings?
Currently, no data Available
What is Oxford BioMedica plc (OXBDF) earnings time?
Currently, no data Available
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OXBDF EPS forecast?
Currently, no data Available
---